New Danish pharmacist Nordisk warned on Monday that hundreds of counterfeit units from its diabetes drug, Ozempic, are being distributed outside its authorized supply chain in the United States.
The country’s health regulator seized counterfeit injections on April 9 and is investigating.
Increased demand for Ozepic, from Novo Nordisk, chemically known as Semaglutado, has raised concerns about unregulated, compound and counterfeit medications. Its weight loss medicine, Wegovy, has the same active ingredient.
While the investigation follows, other analyzes, including an extensive visual examination and chemical tests of the fake product seized, are underway. The US Food and Medicines Agency (FDA) and Novo Nordisk do not yet have information on the identity, quality or safety of medicines, the regulatory agency said on its website.
Novo Nordisk advised retail pharmacies to buy authentic doses of authorized distributors Ozempic and asked patients to check if there are signs of falsification in the product before using the medicine.
This content was originally published in Ozempic manufacturer alerts for falsification wave in the US on the CNN Brazil website.
Source: CNN Brasil
Bruce Belcher is a seasoned author with over 5 years of experience in world news. He writes for online news websites and provides in-depth analysis on the world stock market. Bruce is known for his insightful perspectives and commitment to keeping the public informed.
